Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics Announces Addition of Twirla® to a Preferred Drug Position on Medi-Cal Formulary
Largest Medicaid program in the U.S. adds Twirla to Preferred Drug List as of October 1, 2021 PRINCETON, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX ), a women's healthcare company, announced today that the California Medicaid Program, Medi-Cal, has placed Twirla...
Toggle Summary Agile Therapeutics Announces a Poster Presentation of its SECURE Phase 3 Study at the Contraceptive Technology 2017 Conference
PRINCETON, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, announced a poster presentation of data from the SECURE Phase 3 clinical trial for its lead product candidate, Twirla ® , (ethinyl estradiol and levonorgestrel transdermal...
Toggle Summary Agile Therapeutics Announces 1-For-50 Reverse Stock Split
PRINCETON, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile”), a women's healthcare company, today announced that its board of directors approved a 1-for-50 reverse stock split, to be effective 4:00 p.m. on Monday, April 10, 2023....
Toggle Summary Agile Therapeutics Announces 1-For-40 Reverse Stock Split
PRINCETON, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile”), a women's healthcare company, today announced that the Board approved a 1-for-40 reverse stock split, to be effective 5:00 p.m. on Tuesday, April 26, 2022....
Toggle Summary Agile Therapeutics Announces $7.8 Million Private Placement
PRINCETON, N.J. , March 04, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced today that it has entered into a definitive stock purchase agreement with Perceptive Advisors, LLC , for the private placement of approximately 8.4 million shares...
Toggle Summary Agile Therapeutics Announces $4.85 Million Registered Direct Offering
PRINCETON, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to sell...
Toggle Summary Agile Therapeutics Announces $20 Million Private Placement and Provides Clinical Trial Update
PRINCETON, New Jersey , Jan. 20, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that it has entered into a definitive...
Toggle Summary Agile Therapeutics and Afaxys Partner to Expand Access to Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System
PRINCETON, N.J. and CHARLESTON, S.C., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced a new alliance with Afaxys Pharma, LLC to promote Twirla ® (levonorgestrel and ethinyl estradiol) transdermal system....
Toggle Summary Agile Therapeutics Added to Membership of Russell 2000(R), 3000(R) and Global Indexes
PRINCETON, N.J., June 30, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that its stock has been selected for addition to...
Toggle Summary Agile Therapeutics Acknowledges New Government Guidance Reinforcing Requirement to Cover Contraceptives that a Woman and Her Heathcare Provider Determine are Medically Appropriate at No Cost
PRINCETON, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- On January 10, 2022, the tri-agencies, Department of Labor (DOL), Health and Human Services (HHS) and Treasury issued new guidance that supports women’s access to U.S. Food and Drug Administration (FDA) approved contraceptive products....
Shadow